Business Monitor International


Czech Republic Pharmaceuticals & Healthcare Report

Published 10 April 2014

  • 101 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Czech Republic Pharmaceuticals & Healthcare Report

BMI View: P harmaceutical sales will decline further this year , following the release of poor sales data from the first quarter. Price declines throughout Europe and restructuring of the healthcare system will continue to impact demand within the Czech Republic. We also believe the new centre-left coalition government pos es downside risk to our forecasts given its commitment to containing healthcare costs and improving access to medicines. Despite these concerns, our view is more optimistic over the long term. We believe that the need for innovative medicines will drive growth well above the rates of expansion achieved in Western Europe over our 10-year forecast period. The Czech Republic's disease and drug consumption profile illustrates a considerable gap between it and Western Europe, suggesting that the population's demand for high-value innovative medicines will continue until convergence.

Headline Expenditure Projections

  • Pharmaceuticals: CZK76.93bn (USD3.66bn) in 2013 to CZK74.43bn (USD3.41bn) in 2014; -3.2% in local currency terms and -6.7% in US dollar terms. Forecasts s ignificantly lower compared to previous quarter.

  • Healthcare: CZK290.94bn (USD13.83bn) in 2013 to CZK305.59bn (USD14.02bn) in 2014; +5.0% in local currency terms and 1.3% in US dollar terms. Forecasts changed due to historical revision to 2012 figure s .

Risk/Reward Rating: Despite leading our regional RRR table with a score of 63.2 out of 100 and therefore ranked as the most attractive market in the Central and Eastern European region followed by Poland (61.5) and Russia (57.9) in Q314, drugmakers will face challenges in the Czech pharmaceutical market as a result of pricing pressure, poor access to the market and increasing generic substitution. Additionally, adopted and proposed amendments to healthcare and insurance laws have attracted criticism from the pharmaceutical sector. The Czech pharmaceutical market will nevertheless remain relatively attractive and...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Czech Republic 2010-2018)
18
Healthcare Market Forecast
19
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
22
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Czech Republic 2010-2018)
23
Prescription Drug Market Forecast
24
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
25
Patented Drug Market Forecast
26
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
28
Generic Drug Market Forecast
29
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
30
OTC Medicine Market Forecast
31
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Czech Republic 2010-2018)
33
Pharmaceutical Trade Forecast
34
Table: Pharmaceutical Trade Data And Forecasts (Czech Republic 2012-2018)
35
Table: Pharmaceutical Trade Data And Forecasts local currency (Czech Republic 2012-2018)
36
Other Healthcare Data
37
Key Risks To BMI's Forecast Scenario
38
Macroeconomic Forecasts
39
Table: Czech Republic - Economic Activity
43
Industry Risk Reward Ratings
44
Central And Eastern Europe Risk/Reward Ratings
44
Czech Republic Risk/Reward Ratings
51
Rewards
51
Risks
51
Market Overview
52
Industry Trends And Developments
53
Epidemiology
53
Healthcare Sector
54
Healthcare Insurance
56
Healthcare Reforms
57
Hospital Sector
60
Research & Development
61
Clinical Trials
63
Regulatory Development
65
Regulatory Regime
65
Intellectual Property Environment
65
Prescribing Rules
66
Pharmaceutical Advertising
66
Pricing Regime
67
Reimbursement Regime
68
Recent Pricing And Reimbursement Developments
69
Changes To VAT
72
Table: European VAT Rates On Medicines (%)
73
Electronic Tenders
74
Competitive Landscape
76
Pharmaceutical Sector
76
Foreign Industry
77
Pharmaceutical Wholesale
78
Pharmaceutical Retail Sector
78
Table: Retail Pharmacy Market Overview, 2006-2012
78
Company Profile
80
Zentiva (Sanofi)
80
Walmark
84
AstraZeneca
88
Bristol-Myers Squibb
90
Sanofi
92
Novartis
95
GlaxoSmithKline
97
Pfizer
100
Demographic Forecast
102
Table: The Czech Republic's Population By Age Group, 1990-2020 ('000)
103
Table: The Czech Republic's Population By Age Group, 1990-2020 (% of total)
104
Table: The Czech Republic's Key Population Ratios, 1990-2020
105
Table: The Czech Republic's Rural And Urban Population, 1990-2020
105
Glossary
106
Methodology
108
Pharmaceutical Expenditure Forecast Model
108
Healthcare Expenditure Forecast Model
108
Notes On Methodology
109
Risk/Reward Ratings Methodology
110
Ratings Overview
111
Table: Pharmaceutical Risk/Reward Ratings Indicators
111
Indicator Weightings
112

The Czech Republic Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Czech Republic Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Czech pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Czech Republic to test other views - a key input for successful budgeting and strategic business planning in the Czech pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Czech pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Czech Republic.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc